ANTIBODIES
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
-
Citations
76 Claims
-
1-55. -55. (canceled)
-
56. An antibody or fragment that comprises one or more TIGIT binding sites, wherein each binding site specifically binds to TIGIT and comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain;
- wherein
(i) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
603 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
613;(ii) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
623 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
633;(iii) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
643 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
653;
or(iv) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
663 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO;
673. - View Dependent Claims (57, 58, 59, 60, 61, 62, 63, 64, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)
- wherein
-
65. An anti-TIGIT immunocytokine comprising an immunoglobulin heavy chain and an optionally an immunoglobulin light chain, wherein the immunocytokine comprises an antigen-binding site that specifically binds TIGIT.
Specification